AstraZeneca PLC (AZN)vsConcentra Group Holdings Parent, Inc. (CON)
AZN
AstraZeneca PLC
$161.42
+0.88%
HEALTHCARE · Cap: $263.09B
CON
Concentra Group Holdings Parent, Inc.
$34.06
+11.53%
HEALTHCARE · Cap: $4.05B
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 2649% more annual revenue ($61.37B vs $2.23B). AZN leads profitability with a 17.0% profit margin vs 8.0%. CON trades at a lower P/E of 22.8x. AZN earns a higher WallStSmart Score of 60/100 (C+).
AZN
Buy60
out of 100
Grade: C+
CON
Buy59
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+13.9%
Fair Value
$196.93
Current Price
$161.42
$35.51 discount
Intrinsic value data unavailable for CON.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 21 in profit
Strong operational efficiency at 23.5%
Generating 2.1B in free cash flow
Every $100 of equity generates 42 in profit
Earnings expanding 29.4% YoY
Areas to Watch
Moderate valuation
2.5% earnings growth
Distress zone — elevated risk
Trading at 10.3x book value
8.0% margin — thin
Weak financial health signals
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.0% and operating margin at 23.5%. PEG of 1.47 suggests the stock is reasonably priced for its growth.
Bull Case : CON
The strongest argument for CON centers on Return on Equity, EPS Growth. Revenue growth of 13.7% demonstrates continued momentum.
Bear Case : AZN
The primary concerns for AZN are P/E Ratio, EPS Growth, Altman Z-Score.
Bear Case : CON
The primary concerns for CON are Price/Book, Profit Margin, Piotroski F-Score. Debt-to-equity of 5.00 is elevated, increasing financial risk.
Key Dynamics to Monitor
AZN profiles as a mature stock while CON is a value play — different risk/reward profiles.
CON carries more volatility with a beta of 0.65 — expect wider price swings.
CON is growing revenue faster at 13.7% — sustainability is the question.
AZN generates stronger free cash flow (2.1B), providing more financial flexibility.
Bottom Line
AZN scores higher overall (60/100 vs 59/100), backed by strong 17.0% margins. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Concentra Group Holdings Parent, Inc.
HEALTHCARE · MEDICAL CARE FACILITIES · USA
Concentra Group Holdings Parent, Inc. (Ticker: CON) is a diversified holding company strategically focused on acquiring and managing businesses across high-growth sectors, including healthcare, technology, and infrastructure. With a robust leadership team committed to operational excellence and innovation, Concentra actively seeks to optimize its portfolio through strategic investments and management practices. This proactive approach enables Concentra to effectively leverage emerging market trends and growth opportunities, making it a compelling choice for institutional investors seeking diversification in dynamic and high-potential markets.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?